A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes

<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-017-0499-6"><b>here</b>.</a><br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact <u>[email protected]</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slides<u></u></p

MOESM1 of Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability

Additional file 1: Figure S1. Transfection efficiencies of the use of anti-miR-21 inhibitor evaluated by (A) viability assay using Trypan blue exclusion dye (dil 1:10), and by (B) q-PCR of miR-21 expression levels

Additional file 2: Figure S2. of A donor splice site mutation in CISD2 generates multiple truncated, non-functional isoforms in Wolfram syndrome type 2 patients

Chromatograms of the 400 nt-5′-RACE products not subjected to subcloning. (TIFF 155 kb

MOESM2 of Normoalbuminuric kidney impairment in patients with T1DM: insights from annals initiative

Additional file 2: Table S1. Baseline clinical characteristics of 676 patients with T1DM with low eGFR on the basis of micro- and macro-albuminuria. Table S2. Baseline clinical characteristics of 277 patients with DMT1 with low eGFR on the basis of micro- and macro-albuminuria

MOESM1 of Normoalbuminuric kidney impairment in patients with T1DM: insights from annals initiative

Additional file 1: Fig. S1. Flow-chart of population

Additional file 1: Figure S1. of Diabetic kidney disease in the elderly: prevalence and clinical correlates

Odds Ratios with 99.9% confidence interval (CI) for eGFR< 60 mL/min/1.73 m2 (2A) or albuminuria (2B), by age groups. (TIFF 286 kb

Additional file 2: Figure S2. of Diabetic kidney disease in the elderly: prevalence and clinical correlates

Odds Ratios with 99.9% confidence interval (CI) of Q Score groups for eGFR< 60 mL/min/1.73 m2 or albuminuria, by age groups. (TIFF 134 kb

Clinical characteristics of study patients on the basis of the presence/ absence of metabolic syndrome and hyperuricemia (top gender-specific quintile).

<p>Clinical characteristics of study patients on the basis of the presence/ absence of metabolic syndrome and hyperuricemia (top gender-specific quintile).</p

Clinical data.

<p>Clinical data.</p

A unique plasma microRNA profile defines type 2 diabetes progression

<div><p>A major unmet medical need to better manage Type 2 Diabetes (T2D) is the accurate disease prediction in subjects who show glucose dysmetabolism, but are not yet diagnosed as diabetic. We investigated the possibility to predict/monitor the progression to T2D in these subjects by retrospectively quantifying blood circulating microRNAs in plasma of subjects with i) normal glucose tolerance (NGT, n = 9); ii) impaired glucose tolerance (IGT, n = 9), divided into non-progressors (NP, n = 5) and progressors (P, n = 4) based on subsequent diabetes occurrence, and iii) newly diagnosed T2D (n = 9). We found that impaired glucose tolerance associated with a global increase of plasma circulating microRNAs. While miR-148 and miR-222 were specifically modulated in diabetic subjects and correlated with parameters of glucose tolerance, the most accentuated microRNA dysregulation was found in NP IGT subjects, with increased level of miR-122, miR-99 and decreased level of let-7d, miR-18a, miR-18b, miR-23a, miR-27a, miR-28 and miR-30d in comparison with either NGT or T2D. Interestingly, several of these microRNAs significantly correlated with parameters of cholesterol metabolism. In conclusion, we observed the major perturbation of plasma circulating microRNA in NP pre-diabetic subjects and identified a unique microRNA profile that may become helpful in predicting diabetic development.</p></div